The pharmacotherapy of alcohol dependence: A state of the art review

Mens Sana Monographs

Volumn 8, Issue 1, 2010, Pages 69-82

  De Sousa, Avinash ^a  

^a Human Resource Development   (India)

Author keywords

Acamprosate; Alcohol dependence; Disulfi ram; Naltrexone; Psychopharmacology; SSRIs; Topiramate

Indexed keywords

EID: 75649113446     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.58820     Document Type: Article

References (101)

1. Anton R.F., (2008), Naltrexone for the management of alcohol dependence, New Eng J Med, 359(7), p715-721.
2. Anton R.F., Swift R.M., (2003), Current pharmacotherapies of alcoholism: a US perspective, Am J Addiction, 12(suppl 1), pS53-S68.
3. Banys P., (1988), The clinical use of disulfiram: a review, J Psychoactive Drugs, 20, p243-260.
4. Basu D., Jhirwal O.P., Mattoo S.K., (2005), Clinical characterization of the use of acamprosate and naltrexone: data from an addiction center in India, Am J Addiction, 14, p381-395.
5. Beeson J., Aeby F., Kasas A., Lehert P., Potgieter A., (1998), Combined efficacy of disulfiram and acamprosate in the treatment of alcoholism: a controlled study, Alcohol Clin Exp Res, 22, p573-579.
6. Benjamin D., Grant E.R., Pohorecky L.A., (1991), Naltrexone reverses ethanol induced dopamine release in the nucleus accumbens in awake freely moving rats, Brain Res, 621, p137-140.
7. Berg B.J., Pettinati H.M., Volpicelli J.R., (1996), A risk benefi t analysis of naltrexone in the treatment of alcohol dependence, Drug Saf, 15(4), p274-282.
8. Bouza C., Angeles M., Munoz A., Amate J.M., (2004), Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction, 99, p811-828.
9. Brewer C., (1993), Long term high dose disulfiram treatment of alcohol abuse, Br J Psychiatry, 163, p687-689.
10. Brewer C., (1995), Recent developments in disulfiram treatment, Alcohol Alcohol, 28, p385-393.
11. Brewer C., Hardt F., (1999), Preventing disulfiram hepatitis in alcohol abusers: inappropriate guidelines and the significance of nickel allergy, Addict Biol, 4, p303-308.
12. Brewer C., (2005), Supervised disulfiram is more effective in alcoholism than naltrexone or acamprosate or even psychotherapy: how it works and why it matters, Addiction, 17(4), p222-233.
13. Chick J., Brewer C., (1999), National differences in disulfiram prescribing, Psych Bull, 23, p335-339.
14. Croop R.S., Faulkner E.B., Labriola D.F., (1997), The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group, Arch Gen Psychiatry, 54(12), p1130-1135.
15. Davidson D., Swift R., Fitz E., (1996), Naltrexone increases the latency to drink alcohol in social drinkers, Alcohol Clin Exp Res, 20, p732-739.
16. De Witte P., (2004), Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol, Addict Behav, 29, p1325-1339.
17. De Witte P., Littleton J., Parot P., Koob G., (2005), Neuroprotective and abstinence promoting effects of Acamprosate: elucidating the mechanism of action, CNS Drugs, 19(6), p517-537.
18. DeSousa A., DeSousa A., (2004), Naltrexone versus disulfiram: a one year follow up of alcohol dependence treatment, Alcohol Alcohol, 39, p528-531.
19. DeSousa A., DeSousa A., (2005), An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence, Alcohol Alcohol, 40, p545-548.
20. DeSousa A., DeSousa J.A., Kapoor H., (2008), An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence, J Subs Abuse Treatment, 34, p460-463.
21. DeSousa A., (2008), An open randomized trial comparing disulfiram and naltrexone in the management of adolescents with alcohol dependence, J Substance Use, 13(6), p382-388.
22. Di Chiara G., Imperato A., (1985), Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats, Eur J Pharmacol, 115, p131-132.
23. Drake R.E., Xie H., McHugo G.J., Green A.I., (2000), The effects of Clozapine on alcohol and drug use disorders among patients with schizophrenia, Schizophr Bull, 26, p441-449.
24. Dundon W., Lynch K.G., Pettinati H.M., Lipkin C., (2004), Treatment outcomes in type A and B alcohol dependence 6 months after serotenergic pharmacotherapy, Alcohol Clin Exp Res, 28, p1065-1073. (Pubitemid 38955205)
25. Feeney G.F., Connor J.P., Young R.M., Tucker J., McPherson A., (2006), Combined naltrexone and acamprosate with cognitive behavioral therapy is superior to medication alone for alcohol abstinence: a single Centre's experience with pharmacotherapy, Alcohol Alcohol, 41, p321-327.
26. Finney J.W., Hahn A.C., Moos R.H., (1996), The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on the mediators and moderators of setting effects, Addiction, 91, p1773-1796.
27. Fulton M.K., Kramer G., Moeller F.G., Chae Y., Isbell P.G., Petty F., (1995), Low plasma homovanillic acid levels in recently abstinent alcoholic men, Am J Psychiatry, 152, p1819-1820.
28. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., et al., (1986), Disulfiram treatment of alcoholism: a veterans administration cooperative study, JAMA, 256, p1449-1455.
29. Fuller R.K., Gordis E., (2004), Does disulfiram have a role in alcoholism treatment today? Addiction, 99, p21-24.
30. Garbutt J.C., West S.L., Carrey T.S., Lohr K.N., Crews F.T., (1999), Pharmacological treatment of alcohol dependence: a review of the evidence, JAMA, 281(14), p1318-1325.
31. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., (2005), Efficacy and tolerability of long acting injectable naltrexone for alcohol dependence: a randomized controlled trial, JAMA, 293, p1617-1625.
32. Garbutt J.C., (2006), Emerging pharmacological treatments for the management of alcohol dependence, J Clin Psychiatry, 67(suppl 14), p35-40.
33. Garbutt J.C., (2009), The state of pharmacotherapy for the treatment of alcohol dependence, J Subs Abuse Treat, 36(1), pS15-23.
34. Gessa G.L., Muntoni F., Collu M., Vargiu L., Meeru G., (1985), Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area, Brain Res, 348, p201-203.
35. Gianoulakis C., (1993), Endogenous opioids and excess alcohol consumption, J Psychiatry Neurosci, 18(4), p148-156.
36. Grover S., Bhateja G., Basu D., (2007), Pharmacoprophylaxis of alcohol dependence: review and update Part I: Pharmacology, Indian J Psychiatry, 49, p19-25.
37. Guardia J., Segura L., Gonzalvo B., Iglesias L., Roncero C., Cardus M., et al., (2004), A double blind placebo controlled study of olanzapine in the treatment of alcohol dependence disorder, Alcohol Clin Exp Res, 28, p736-745.
38. Harris R.A., Erickson C.K., (1979), Alteration of ethanol effects by opiate antagonists, Curr Alcohol, 5, p17-28.
39. Heimer L., Alheid G.F., (1991), Piecing together the puzzle of basal forebrain anatomy, Adv Exp Med Biol, 295, p1-42.
40. Herz A., (1997), Endogenous opioid systems and alcohol addiction, Psychopharmacology, 129, p99-111.
41. Hoffman P.L., (2003), NMDA receptors in alcoholism, Int Rev Neurobiol, 56, p35-82.
42. Hughes J.C., Cook C.C., (1997), The efficacy of disulfiram: a review of outcome studies, Addiction, 92, p381-395.
43. Jaffe A.J., Rounsaville B., Chang G., Schottenfield R.S., Mayer R.E., O'Malley S.S., (1996), Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient treatment matching, J Consult Clin Psychol, 64(5), p1044-1053.
44. Johnsen J., Merland J., (1991), Disulfiram implant: a double blind placebo controlled follow up on treatment outcome, Alcohol Clin Exp Res, 15(3), p532-536.
45. Johnsen J., Merland J., (1992), Depot preparations of disulfiram: experimental and clinical results, Acta Psych Scand, 86, p27-30.
46. Johnson B.A., Roache J.D., Javors M.A., DiClemente C.C., Cloninger R.C., Prihoda T.J., et al., (2000), Ondansetron for the reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial, JAMA, 284, p963-971.
47. Johnson B.A., Ait-Daoud N., Bowden C.L., DeClemente C.C., Roache J.D., Lawson K., (2003), Oral topiramate in the treatment of alcohol dependence: a randomized controlled trial, Lancet, 361, p1677-1685.
48. Johnson B.A., Ait-Daoud N., Aubin H.J., Van Den Brink W., Guzetta R., Loewy J., (2004), A pilot evaluation of the safety and tolerability of long acting injectable naltrexone in patients with alcohol dependence, Alcohol Clin Exp Res, 28, p1356-1361.
49. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., et al., (2003), Comparing and combining naltrexone and acamprosate in the relapse prevention of alcoholism: a double blind placebo controlled trial, Arch Gen Psychiatry, 60, p92-99.
50. King A.C., Volpicelli J.R., Frazer A., O'Brien C.P., (1997), Effect of naltrexone on subjective alcohol response in subjects with high and low risk for future alcohol dependence, Psychopharmacology, 129, p15-22.
51. King A.C., Cao D., Vanier C., Wilcox, T., (2009), Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study, Alcohol Clin Exp Res, 33(6), p1044-1050.
52. Kranzler H.R., Burleson J.A., Korner P., Babor T.F., (1996), Fluoxetine treatment seems to reduce the beneficial effects of cognitive behavioral therapy in type B alcoholics, Alcohol Clin Exp Res, 20, p1534-1541.
53. Kranzler H.R., (2000), Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research, Alcohol Alcohol, 35(6), p537-547.
54. Kranzler H.R., Wesson D.R., Billot L.; Drug Abuse Science Naltrexone Depot Study Group (2004), Naltrexone depot for the treatment of alcohol dependence: a multicenter randomized placebo controlled trial, Alcohol Clin Exp Res, 28, p1051-1059.
55. Kranzler H.R., (2006), Evidence based treatments for alcohol dependence: new results and new questions, JAMA, 295, p2075-2076.
56. Laaksonen E., Koski-Jannes A., Salaspuro M., Ahtinen H., Alho H., (2008), A randomized multicentre open labeled trial comparing disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence, Alcohol Alcohol, 43(1), p53-61.
57. Lundwall L., Baekeland F., (1971), Disulfiram treatment of alcoholism, J Nerv Ment Dis, 153(6), p381-394.
58. Makela P., Martikainen P., Nihtila E., (2005), Temporal variations in deaths related to alcohol intoxication and drinking, Int J Epidemiol, 34(4), p765-771.
59. Mann K., (2004), Pharmacotherapy of alcohol dependence: a review of the clinical data, CNS Drugs, 18(8), p485-504.
60. Mann K., Lehert P., Morgan M.Y., (2004), The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: results of a meta-analysis, Alcohol Clin Exp Res, 28, p51-63.
61. Marra D., Warot D., Berlin I., Hispard E., Notides C., Tilkete S., et al., (2002), Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized placebo controlled trial, Alcohol Clin Exp Res, 26, p1545-1552.
62. Martin B., Beresford T.P., (2007), Disulfiram in context, structure and safety, J Clin Psychopharmacol, 27(4), p415-417.
63. Mason B.J., (1996), Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res, 20(Suppl 7), p10A-16A.
64. Mason B.J., (2001), Treatment of alcohol dependent out patients with Acamprosate: a clinical review, J Clin Psychiatry, 62 (suppl 20), p42-48.
65. Mason B.J., (2003), Acamprosate and Naltrexone treatment for alcohol dependence: an evidence based risk benefi ts assessment, Eur Neuropsychopharmacol, 13(6), p469-475.
66. Mason B.J., (2005), Acamprosate in the treatment of alcohol dependence, Exp Opin Pharmacother, 6(12), p2103-2115.
67. Mason B.J., (2005), Rationale for combining acamprosate and naltrexone in the treatment of alcohol dependence, J Stud Alcohol, Suppl, p148-156.
68. Melchior J.A., Hoes J.M., (1999), Relapse prevention in alcoholics: a review of acamprosate versus naltrexone, Clin Drug Invest, 17, p211-216.
69. Modell J.G., Mountz J.M., Glaser F.B., Lee J.Y., (1993), Effect of Haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res, 17(2), p234-240.
70. Monti P.M., Rosenhow D.J., Hutchison K.L., Swift R.M., Mueller T.I., Colby S.M., et al., (1999), Naltrexone's effect on cue elicited carving among alcoholics in treatment, Alcohol Clin Exp Res, 23, p1386-1394.
71. Murray C.J., Lopez A.D., (1997), Global mortality, disability and contribution of risk factors, Lancet, 349, p1436-1442.
72. Naidu H., Thacore A.S., Koshy M.K., (2000), Naltrexone in alcohol dependence: a comparison with disulfiram, Ind J Psychiatry, 41, p43-44.
73. Nunes E.V., Levin F.R., (2004), Treatment of depression in patients with alcohol and other forms of drug dependence, JAMA, 291, p1887-1896.
74. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H.M., Gelernter J., Volpicelli J.R., et al., (2003), A functional polymorphism of the mu opioid receptor gene is associated with naltrexone response in alcohol dependent patients, Neuropsychopharmacology, 28, p1546-1552.
75. O'Malley S.S., Jaffe A.J., Chang G., Schottenfield R.S., Mayer R.E., (1992), Naltrexone and coping skills therapy for alcohol dependence: a controlled study, Arch Gen Psychiatry, 49, p881-887.
76. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., Parot P., (1995), Double blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol, Alcohol Alcohol, 30, p239-247.
77. Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., Lehert P., (1997), Efficacy and safety of acamprosate in the treatment of detoxifi ed alcohol dependent patients: a 90 day placebo controlled dose fi nding study, Br J Psychiatry, 171, p73-77.
78. Petrakis I.L., Poling J., Levinson C., Nich C., Caroll K., Ralevski E., et al., (2006), Naltrexone and disulfiram in patients with alcohol dependence and comorbid post traumatic stress disorder, Biol Psychiatry, 60(7), p777-783.
79. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.M., Oslin D.W., Kampman K.M., et al., (2006), The status of Naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking, J Clin Psychopharmacol, 26, p610-625.
80. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R., et al., (2008), A double blind placebo controlled trial that combines naltrexone and disulfiram in the treatment of cocaine and alcohol dependent patients, Addict Behav, 33(5), p651-667.
81. Poulsen E.H., (1992), Disulfiram therapy - adverse drug reactions and interactions, Acta Psych Scand, 86, p59-66.
82. Richardson K., Baillie A., Reid S., Morley K., Teeson M., Saanibale C., et al., (2008), Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 103(6), p953-959.
83. Rosenthal R.N., (2006), Current and future drug therapies for alcohol dependence, J Clin Psychopharmacol, 26 (Supp 1), pS20-S29.
84. Rubio G., Jimenez-Arriero M.A., Ponce G., Palamo T., (2001), Naltrexone versus acamprosate: one year follow up of alcohol dependence treatment, Alcohol Alcohol, 36, p419-425.
85. Sass H., Soyka M., Mann K., Zeiglgansberger W., (1996), Relapse prevention by acamprosate. Results from a placebo controlled trial on alcohol dependence, Arch Gen Psychiatry, 53, p673-680.
86. Savas M.C., Gullu J.H., (1997), Disulfiram ethanol reaction - the significance of supervision, Annals Pharmacother, 31, p374-375.
87. Schadlich P.K., Brecht J.G., (1998), The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) study, Pharmacoeconomics, 13(6), p719-730.
88. Skradski S., White H.S., (2000), Topiramate blocks kainite evoked cobalt infl ux into cultured neurons, Epilepsia, 41(Suppl 1), pS45-S47.
89. Srisurapanont M., Jarusuraisin N., (2005), Naltrexone for the treatment of alcoholism: a meta analysis of randomized controlled trials, Int J Neuropsychopharmacol, 8, p267-280.
90. Streeton C., Wheelan G., (2001), Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta analysis of randomized controlled trials, Alcohol Alcohol, 36(6), p544-552.
91. Suh J.J., Pettinati H.M., Kampman K.M., O'Brien C.P., (2006), The status of Disulfiram: a half of a century later, J Clin Psychopharmacol, 26, p290-302.
92. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H., (1994), Naltrexone induced alterations in human ethanol intoxication, Am J Psychiatry, 151(10), p1463-1467.
93. Swift R.M., (1999), Drug therapy for alcohol dependence, New Eng J Med, 340, p1482-1490.
94. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P., (1992), Naltrexone in the treatment of alcohol dependence, Arch Gen Psychiatry, 49, p876-880.
95. Walters D., Connors J.P., Feeney G.F., Young R.M., (2009), The cost effectiveness of Naltrexone added to cognitive behavioral therapy in the treatment of alcohol dependence, J Addict Dis, 28(2), p137-144.
96. Weiss R.D., Kueppenbender K.D., (2006), Combining psychosocial treatments with pharmacotherapy for the management of alcohol dependence, J Clin Psychopharmacol, Suppl 1, pS37-S42.
97. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., Wolf H.H., (2000), Topiramate modulates GABA evoked currents in murine cortical neurons by non benzodiazepine mechanisms, Epilepsia 41 (Suppl 1), pS17-S20.
98. Wilde M.I., Wagstaff A.J., (1997), Acamprosate. A review of its pharmacology and its clinical potential in the management of alcohol dependence after detoxification, Drugs, 53, p1038-1053.
99. Wilkins J.N., (2006), Traditional pharmacotherapy for alcohol dependence, J Clin Psychiatry, 67(suppl 14), p17-22.
100. Wisebeck G.A., Weijers H.G., Lesch O.M., Glaser T., Toennes P.J., Boening J., (2001), Fluphenthixol decanoate and relapse prevention in alcoholics: results from a placebo controlled study, Alcohol Alcohol, 36, p329-334.
101. Yen M.H., Ko H.C., Tang F.I., Lu R.B., Hong J.S., (2006), Study of hepatotoxicity of Naltrexone in the treatment of alcoholism, Alcohol, 38(2), p117-120.